Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02915016 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 334
- Enrollment target
NCT02915016 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 334 participants.
The verdict
NCT02915016, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 334 participants
- Enrollment target
Study Summary
This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL DNA-HIV-PT123 vaccine
- BIOLOGICAL Bivalent Subtype C gp120/MF59 vaccine
- BIOLOGICAL Bivalent Subtype C gp120/AS01B vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2016-12-07 |
| Est. Completion | 2020-02-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02915016
The ClinicalTrials.gov registry entry for NCT02915016 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02915016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02915016 about?
NCT02915016 is a clinical study titled "Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults". This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.
What is the current status of trial NCT02915016?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 334 participants. The study started on 2016-12-07. Estimated completion is 2020-02-12.
What interventions are being tested in trial NCT02915016?
The interventions under investigation include: Placebo (BIOLOGICAL), DNA-HIV-PT123 vaccine (BIOLOGICAL), Bivalent Subtype C gp120/MF59 vaccine (BIOLOGICAL), Bivalent Subtype C gp120/AS01B vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02915016?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.